| Identification | Back Directory | [Name]
PAZ 417 | [CAS]
481629-87-2 | [Synonyms]
PAZ 417
Aleplasinin
HSXLMAFNWCSZGP-UHFFFAOYSA-N
2-(1-(4-(tert-butyl)benzyl)-5-(m-tolyl)-1H-indol-3-yl)-2-oxoaceticacid
Plasminogen activator inhibitor-1,PAI-1,Serpin family,Abeta,inhibit,Inhibitor,Amyloid-β,Alzheimer's disease,BBB-penetrated,β-amyloid peptide,orally active,Aleplasinin,memory deficiency | [Molecular Formula]
C28H27NO3 | [MDL Number]
MFCD18072005 | [MOL File]
481629-87-2.mol | [Molecular Weight]
425.519 |
| Chemical Properties | Back Directory | [Melting point ]
128-129 °C | [Boiling point ]
616.9±47.0 °C(Predicted) | [density ]
1.13±0.1 g/cm3(Predicted) | [storage temp. ]
4°C, protect from light | [solubility ]
DMSO : 250 mg/mL (587.52 mM; Need ultrasonic) | [form ]
Solid | [pka]
2.13±0.54(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
Aleplasinin is an orally active, potent, BBB-penetrated and selectiveSERPINE1 (PAI-1, Plasminogen activator inhibitor-1) inhibitor. Aleplasinin increases amyloid-β (Aβ) catabolism and ameliorates amyloid-related pathology. Aleplasinin improves memory deficiency. Aleplasinin can be used for Alzheimer's disease research[1][2]. | [storage]
4°C, protect from light | [References]
[1] Zhao J, Pei G. Evoking plasmin for beta-amyloid clearance. Cell Res. 2008 Aug;18(8):803-4. DOI:10.1038/cr.2008.89
[2] Kellici TF, Pilka ES, Bodkin MJ. Therapeutic Potential of Targeting Plasminogen Activator Inhibitor-1 in COVID-19. Trends Pharmacol Sci. 2021 Jun;42(6):431-433. DOI:10.1016/j.tips.2021.03.006 |
|
|